EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities such as thinking, language, and learning capacity. Mild cognitive impairment (MCI) is a condition of the elderly in which there is a slight but noticeable and measurable decline in cognitive abilities, including memory loss and thinking skills, but no dementia. MCI presents as an intermediate stage between the cognitive decline that occurs with normal aging and the onset of dementia.
To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM, GlobalData epidemiologists utilized country-specific population-based studies. GlobalData epidemiologists further categorized the AD total prevalent cases based on severity as mild, moderate, and severe. Similarly, GlobalData epidemiologists selected country-specific studies with a consistent definition of MCI to forecast the total prevalent cases of MCI in the 7MM. GlobalData epidemiologists kept the forecast methodology consistent across the 7MM in order to allow for a meaningful comparison of the forecast total prevalent cases across the markets.
In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of AD from 10,604,756 total prevalent cases in 2016 to 13,759,918 total prevalent cases in 2026, at an annual growth rate (AGR) of 2.98% during the forecast period. Among the 7MM, the US will have the highest number of total prevalent cases of AD throughout the forecast period, while the UK will have the lowest.
Scope
The Alzheimer’s Disease (AD) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of AD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age (ages 60 years and older) in these markets.
The AD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The Alzheimer’s Disease EpiCast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global AD market.
Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
Understand severity of prevalent AD cases and total prevalent cases of MCI.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.